Allogeneic Hematopoietic Cell Transplantation in Elderly Patients in a Latin American Country: Analysis of 11 Years of Data from the Brazilian Registry SBTMO/CIBMTR

This study analyzed recent changes in the utilization of allogeneic HCT for treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative diseases (MPD) and the survival of HCT recipients ≥60 years of age in Brazil. This retrospective registry study included patie...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transplantation and cellular therapy 2024-12
Hauptverfasser: Duarte, Fernando Barroso, Garcia, Yhasmine Delles Oliveira, Hamerschlak, Nelson, Funke, Vaneuza Araújo Moreira, Moreira, Maria Claudia Rodrigues, Paz, Alessandra Aparecida, Filho, Jayr Schmidt, Astigarraga, Claudia Caceres, da Silva, Roberto Luiz, de Molla, Vinícius Campos, Silvério, Alexandre, Rocha, Vanderson Geraldo, Feliciano, João Victor Piccolo, Barros, George Maurício Navarro, Colturato, Vergílio Antônio Rensi, Nabhan, Samir Kanaan, Farias, João Samuel de Holanda, Maia, Ana Carolina Arrais, Atalla, Ângelo, Chiattone, Ricardo, Macedo, Maria Cristina Martins de Almeida, Aranha, Milton Alexandre Ferreira, Zogbi, Yana Augusta Novis, Lener, Décio, Soares, Rodolfo Daniel de Almeida, Scheinberg, Phillip, Calixto, Rodolfo Froes, Teixeira, Gustavo Machado, Colella, Marcos Paulo, Rodrigues, Celso Arrais, Simione, Anderson João, da Silva, Cinthya Corrêa, Martin, Paul J, Flowers, Mary E
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This study analyzed recent changes in the utilization of allogeneic HCT for treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative diseases (MPD) and the survival of HCT recipients ≥60 years of age in Brazil. This retrospective registry study included patients who received a first allogeneic HCT from any donor between 2012 and 2023. Of the 6657 patients, 444 (7%) were 60 years of age or older who received grafts from HLA-matched related (42%) or unrelated (20%) donors or HLA-haploidentical donors (32%). The proportion of HCT recipients 60 years of age or older increased gradually from 3.2% in 2012 to 16% in 2023 mostly due to the increased use of HLA-haploidentical donors since 2018. Overall survival (OS) at day 100 was 77%, and estimated OS at 12 months was 53% (95% CI, 48-58). OS at 12-months was higher for transplants during 2015-2017 (58%) and 2018-2020 (68%) compared to 2012-2014 (45%), but it did not differ for those during 2021-2023 (49%). Mortality with HLA-haploidentical donors (HR 2.35; 95%CI; 1.65-3.34 [p
ISSN:2666-6367